Janux Therapeutics JANX
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 88th percentile, 5-year average -16.9x
Near the bottom of its 5-year range · 0th percentile, 5-year average 2.1x
#1026 of 5329 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 0th percentile, 5-year average 306.4x
#4802 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 0.76 | – | 2.08 | 0% (cheaper than usual) | #1026 of 5329 (1 = cheapest) |
| PE | -7.15 | -4.80 | -16.91 | 88% (pricier than usual) | – |
| PS | 29.87 | 89.07 | 306.37 | 0% (cheaper than usual) | #4802 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on JANX.
Sign in to join the discussion.